Postpartum depression affects roughly 1 in 7 new mothers, causing persistent sadness, anxiety, difficulty bonding with the baby, and — in severe cases — thoughts of self-harm. It remains dramatically underrecognized and undertreated, and effective treatment exists.
What's actually going on in research
Zuranolone, an oral neurosteroid that rapidly modulates GABA-A receptors, is now approved for postpartum depression with a 14-day course that works far faster than traditional antidepressants. Brexanolone (an IV neurosteroid) is the first drug specifically designed for PPD. Trials are testing telehealth delivery of psychotherapy, peer support models, and digital interventions to reach the many mothers who never access formal care.
Neurosteroid treatment
Zuranolone (oral) and brexanolone (IV) act on GABA-A receptors to rapidly reduce postpartum depression symptoms in days rather than weeks, representing a new mechanism class.
Digital and telehealth therapy
App-based CBT and telehealth-delivered interpersonal therapy are being tested for postpartum depression, potentially reaching mothers who face barriers to in-person mental health care.
Peer support programs
Structured programs pairing mothers with trained peer supporters who have recovered from PPD are in trials for their ability to reduce symptoms and improve treatment engagement.
What to know before you search
Eligibility requires a postpartum depression diagnosis within a defined number of weeks after delivery, depression severity threshold, and exclusion of psychosis or bipolar features.
What types of trials are currently open
- Drug trials — Testing neurosteroids, antidepressants, and novel agents for postpartum depression symptom relief.
- Psychotherapy trials — Comparing CBT, interpersonal therapy, and other structured psychotherapies delivered in-person and digitally.
- Prevention trials — Testing progesterone supplements, psychoeducation, and support interventions in high-risk pregnant women.
- Digital intervention trials — Evaluating app-based and telehealth programs to extend access to postpartum depression treatment.
- Observational studies — Tracking PPD screening rates, treatment access, and child developmental outcomes.
Recently added Postpartum Depression trials
Predictive Value of Early Peritraumatic Distress Screening for Childbirth-PTSD Following Unplanned Cesarean Delivery
The goal of this observational study is to learn whether early postpartum screening tools can predict the development of childbirth-related post-traumatic stress symptoms in individuals who undergo unplanned cesarean delivery. The main questions it aims to answer are: * Do scores on the Peritraumatic Distress Inventory (PDI) collected 24-48 hours after delivery predict childbirth-related PTSD symptoms at 6 weeks postpartum? * Do scores on the City Birth Trauma Scale - Short Form (CityBiTS-SF) collected 24-48 hours after delivery predict childbirth-related PTSD symptoms at 6 weeks postpartum? Participants will: * Complete questionnaires within 24-48 hours after delivery, including the PDI, CityBiTS-SF, and Edinburgh Postnatal Depression Scale (EPDS). * Complete follow-up questionnaires at 6 weeks and 3 months postpartum, including measures of PTSD symptoms (PTSD Checklist for DSM-5, PCL-5) and depressive symptoms. Researchers will evaluate whether early screening scores are associated with later symptoms of childbirth-related PTSD and postpartum depression, and will assess the feasibility and acceptability of implementing routine inpatient screening for psychological birth trauma.
Try sexual health counseling sessions during pregnancy
This experimental, randomized controlled, single-blind study includes intervention and control groups. Pregnant women between 16 and 20 weeks of gestation who meet the inclusion criteria and agree to participate will be included in the study. Pregnant women will be randomly assigned to groups. Pre-test data will be collected from both groups. The intervention group will receive sexual counseling training in two sessions, face-to-face and in groups, until week 22. Second test data will be collected after week 37 (before delivery), and final test data will be collected three months after delivery. This study is expected to have a significant impact on women's lives, as this topic is considered taboo in our country, leading to a lack of open discussion and the prevalence of misconceptions and false beliefs (sexual myths).
Find Postpartum Depression trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.